Hilltop Leaf is currently undergoing its application to the U.K. regulators for the appropriate licences to handle and produce CBPMs.
A ‘Cannabis-based product for medicinal use in humans’ is defined as:
““cannabis-based product for medicinal use in humans” means a preparation or other product, other than one to which paragraph 5 of part 1 of Schedule 4 applies, which—
(a) is or contains cannabis, cannabis resin, cannabinol or a cannabinol derivative (not being dronabinol or its stereoisomers);
(b) is produced for medicinal use in humans; and—
(c) is—
—(i) a medicinal product, or
—(ii) a substance or preparation for use as an ingredient of, or in the production of an ingredient of, a medicinal product;”;
